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Summary
Recent studies on the immunopathology of multiple
sclerosis revealed a heterogeneity in the patterns of
demyelination, suggesting interindividual differences in
the mechanism responsible for myelin destruction. One
of these patterns of demyelination, characterized by
oligodendrocyte dystrophy and apoptosis, closely mimics
myelin destruction in acute white matter ischaemia. In
the course of a systematic screening for virus antigen
expression in multiple sclerosis brains, we identi®ed a
monoclonal antibody against canine distemper virus,
which detects a cross-reactive endogenous brain epitope,
highly expressed in this speci®c subtype of actively
demyelinating multiple sclerosis lesions with little or no
immunoreactivity in other active multiple sclerosis
cases. The respective epitope, which is a phosphoryl-
ation-dependent sequence of one or more proteins of 50,
70 and 115 kDa, is also expressed in a subset of active
lesions of different virus-induced in¯ammatory brain
diseases, but is present most prominently and consist-
ently in acute lesions of white matter ischaemia. Its
presence is signi®cantly associated with nuclear expres-
sion of hypoxia-inducible factor-1a within the lesions of
both in¯ammatory and ischaemic brain diseases. The
respective epitope is liberated into the CSF and, thus,
may become a useful diagnostic tool to identify clinic-
ally a de®ned multiple sclerosis subtype.
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Abbreviations: BND = bacterial-induced neurological disease; CDV = canine distemper virus; ELISA = enzyme-linked
immunosorbent assay; FBS±PBS = fetal calf serum±phosphate-buffered saline; HIF-1a = hypoxia-inducible factor-1a;
Ig = immunoglobulin; OND: non-in¯ammatory neurological diseases; PBS = phosphate-buffered saline; PBS-T =
phosphate-buffered saline±0.05% Tween-20; PCR = polymerase chain reaction; PLP = proteolipid protein; SDS = sodium
dodecylsulfate; VND = viral-induced neurological disease
Introduction
By analysing a large sample of biopsy and autopsy cases of
multiple sclerosis in the active stage of demyelination, we
were able to de®ne four distinctly different patterns of
demyelination, which were heterogenous between patients,
but homogenous within multiple active lesions of a single
patient (Lucchinetti et al., 1999, 2000). This observation may
have therapeutic consequences, when it is possible to identify
these different pathways of demyelination by clinical or
paraclinical markers in the living patient.
One speci®c pattern of demyelination is de®ned by an
oligodendrogliopathy, primarily affecting the most distant
processes of these cells and leading to apoptotic cell death of
oligodendrocytes at later stages of lesion development
(Lucchinetti et al., 2000). These alterations of oligodendro-
cytes and myelin are similar to those present in acute
ischaemic white matter damage and are associated with
nuclear expression of hypoxia-inducible factor-1a (HIF-1a).
Here we describe that a monoclonal antibody against the
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nucleocapsid protein of canine distemper virus (CDV) cross-
reacts with an antigen which is expressed with a high degree
of selectivity in these particular multiple sclerosis patients as
well as in acute stroke lesions. Since the antigen is liberated
into the CSF, the antibody may become a useful paraclinical
tool to identify a pathogenetically distinct subtype of multiple
sclerosis patients.
Material and methods
Autopsy and biopsy cases
The study was performed on archival paraformaldehyde-®xed
paraf®n-embedded tissue samples from 101 patients, col-
lected at the Brain Research Institute of Vienna University.
Clinical diagnosis and demographic data are summarized in
Table 1.
The multiple sclerosis population contained all different
clinical variants of the disease. Furthermore, all different
patterns of demyelination, as de®ned by Lucchinetti et al.
(2000), were included in the sample. Two to ®ve represen-
tative tissue blocks were investigated per case. Active
demyelination within the lesions was classi®ed according to
BruÈck et al. (1995) by the presence of macrophages with
myelin degradation products, immunoreactive for myelin
proteins.
In addition to these autopsy cases, four brain biopsies,
performed for diagnostic reasons, were available (Table 2). In
these patients, multiple serum and CSF samples were
collected at various time points of disease development. All
biopsy patients suffered from an acute, fulminant neuro-
logical disease with multifocal large lesions in the cerebral
white matter. Biopsy diagnosis revealed an acute in¯amma-
tory demyelinating process, consistent with acute multiple
sclerosis. More detailed immunopathological classi®cation
showed that three patients had lesions compatible with
antibody-mediated demyelination, while the other one
contained lesions with distal oligodendrogliopathy and
oligodendrocyte apoptosis.
CSF samples
CSF samples were obtained for diagnostic purposes between
1993 and 2001 from patients who gave informed consent, and
were stored at ±20°C until use. The clinical and CSF data of
all patients analysed in this study are shown in Table 1.
Multiple sclerosis patients (n = 93) were diagnosed according
to the criteria of Poser et al. (1983). In addition, 12 patients
with cerebrovascular disease (stroke), 13 patients with viral
neurological diseases (VND; viral meningitis, meningoence-
phalitis and encephalitis), 10 patients with bacterial
neurological diseases (BND; bacterial meningitis and
Table 1 Clinical data
Tissue samples n M/F ratio Age (years)* Disease duration* Cells* IgG Ind* Q-Alb*
Acute MS 11 1.2 48 6 11 6.5 6 6.7 weeks
Chronic active MS 12 3.5 39 6 11 4.5 6 3 years
Chronic inactive MS 11 2 68 6 11 25.9 6 8.2 years
CMV enceph. 8 0 (8 M) 40 6 10 11.3 6 3.5 weeks
HSV enceph. 6 0.5 48 6 24 2.6 6 0.9 weeks
PML 11 0.1 41 6 9 31.2 6 30.3 weeks
FSME 5 0.6 61 6 12 3.9 6 3.2 weeks
HIV enceph. 5 0 (5 M) 38 6 7 13.5 6 3.5 weeks
SSPE 2 1 30 6 12 40; >500 weeks
Stroke 13 1.2 80 6 11 29.8 6 53.2 weeks
Controls 9 0.8 69 6 22 NA
Myo. infarcts 8 1.67 54 6 7 41 6 28 months+
CSF studies
MS R0 43 1.6 33 6 11 0 6 0 years 9 6 25 1.1 6 0.6 5 6 3
MS RR 25 3.1 34 6 8 4 6 3 years 5 6 5 1.1 6 0.9 5 6 1
MS SP 14 2.5 47 6 13 17 6 11 years 3 6 8 1.1 6 0.9 8 6 7
MS PP 10 1 51 6 12 6 6 5 years 5 6 5 0.9 6 0.5 7 6 2
Stroke 12 1 58 6 15 8 6 6 days 9 6 25 0.6 6 0.4 18 6 43
VND 13 1.14 52 6 17 12 6 13 days 80 6 124 0.6 6 0.3 10 6 9
BND 10 9 47 6 23 5 6 3 days 2028 6 2723 0.7 6 0.2 17 6 32
OND 46 1.42 48 6 15 5 6 4 1 6 1 0.5 6 0.1 2 6 2
BD 31 1.07 45 6 10
Cells = CSF cells/ml; IgG Ind = CSF IgG index; Q-Alb = albumin quotient; R0 = ®rst attack; RR = relapsing±remitting disease course;
SP = secondary chronic progressive disease course; PP = primary chronic progressive disease course; VND = viral neurological diseases;
BND = bacterial neurological diseases; OND = other neurological diseases; BD = blood donors; Myo. infarcts = myocardial infarcts;
MS = multiple sclerosis; CMV encephal. = cytomegalovirus encephalitis; HSV encephal. = herpes simplex virus encephalitis;
FSME = European tick-borne encephalitis; HIV encephal. = human immunode®ciency virus encephalitis; PML = progressive multifocal
leucoencephalopathy; NA = not available. *Mean values with SDs. +Clinical duration of heart disease; the samples contained fresh
myocardial infarcts at different stages of lesion development.
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meningoencephalitis) and 46 patients with other neurological
diseases (OND; headache, back pain and disc protrusion)
were included in this study.
Antibodies and reagents
CDV antibodies
Monoclonal antibody D-110 detects an epitope within the C-
terminus (between amino acids 412 and 523) of the CDV
nucleocapsid (N) protein. This antibody binds to all CDV
strains (Bollo et al., 1986; Hamburger et al., 1991). Six
additional monoclonal antibodies recognizing other epitopes
of the N protein, two monoclonal antibodies binding to the
surface glycoprotein H and one monoclonal antibody binding
to the auxiliary nucleocapsid protein M were included
(Table 3). The speci®city of all antibodies was determined
by immunoprecipitation and on western immunoblots, and
their suitability for the detection of CDV in paraf®n sections
was established in dog brain lesions of CDV encephalitis
(MuÈller et al., 1995; Zurbriggen et al., 1995). Since D-110 is a
mouse immunoglobulin Ig G1 antibody, we used other IgG1
antibodies against irrelevant antigens as controls for im-
munocytochemistry and western blotting.
CDV in situ hybridization probes
For in situ hybridization, digoxigenin-labelled RNA probes
were used (Table 3; Zurbriggen et al., 1995). Two probes
complementary to the N-speci®c sequence of the virulent
A75/17 CDV were selected, because the D-110 antibody
recognizes an epitope within the N protein of CDV. A probe
complementary to the P-speci®c sequence of CDV (P in
Table 3) was chosen, because it has been shown to be the
most sensitive marker for CDV RNA in distemper. All probes
have been tested positive on paraformaldehyde-®xed paraf®n-
embedded tissue samples from dogs with canine distemper
encephalitis.
Other immunocytochemical markers
Primary antibodies were used against the following targets:
myelin oligodendrocyte glycoprotein (Piddlesden et al.,
1993), myelin-associated glycoprotein (D7E10 and B11F7;
Doberson et al., 1985), cyclic nucleotide phosphodiesterase
(Af®nity Research Products, Manhead Castle, Exeter, UK),
proteolipid protein (PLP; Serotec, Oxford, UK) and HIF-1a
(BD Transduction Laboratories, Lexington, KY, USA).
Table 3 CDV antibodies for immunohistochemistry
Monoclonal antibody CDV protein Reference
D-110 NP Hamburger et al. (1991)
D-15 NP Dubacher (1988)
D-150 NP Dubacher (1988)
a3H-10 NP Hamburger et al. (1991)
K4-2 NP Dubacher (1988)
3991 NP Dubacher (1988)
4996 NP Dubacher (1988)
3570 NP Dubacher (1988)
XI-6 M Dubacher (1988)
XI-23 H Dubacher (1988)
CDV probes for ISH mRNA Reference
NP-3 NP Zurbriggen et al. (1995)
NP-1 NP Zurbriggen et al. (1995)
P-3 P MuÈller et al. (1995)
ISH = in situ hybridization; NP = nucleocapsid protein N epitope;
M = nucleocapsid protein M; H = glycoprotein H; P = P-speci®c
sequence of CDV.
Table 2 Expression of D-110 epitope in the CSF of acute multiple sclerosis patients
Patient/age/gender Disease duration
before biopsy
Date of biopsy Date of CSF
examination
Biopsy pathology CSF D-110
(OD units)
B/22/female
active disease
4 months 2/17/00 8/17/00 MS pattern II 0.233
K/26/male
active disease
1 month 3/3/99 2/26/99 MS pattern II 0.244
Ha1/24/male MRI after car
accident revealed
multiple enhancing
supratentorial
lesions
4/12/01 3/29/01 MS pattern II 0.248
Ha2 6/13/01 0.217
Ha3 7/2/01 0.232
Ha4 10/5/01 0.248
Kr1/33/male
active disease
1 month 5/4/00 5/9/00 MS pattern III 0.419
Kr2 active disease 5/16/00 0.422
Kr3 remission 5/29/00 0.250
MS pattern II = multiple sclerosis pattern II demyelination; MS pattern III = multiple sclerosis pattern III demyelination. CSF samples
Ha2, 3, 4, Kr2 and 3 are follow up samples of patients Ha1 and Kr1, respectively.
CSF marker for tissue damage in multiple sclerosis lesions 1349
Neuropathology and immunocytochemistry
Paraf®n sections were stained with haematoxylin/eosin, luxol
fast blue for myelin and Bielschowsky silver impregnation for
axons. Immunocytochemistry was performed with a bio-
tin±avidin technique (Vass et al., 1986). Microwave pre-
treatment was used in tissue samples with prolonged formal-
dehyde ®xation time. Non-radioactive in situ hybridization
was used with digoxygenin-labelled riboprobes using the
Boehringer Kit (Breitschopf et al., 1992). For dephosphor-
ylation, sections were pre-treated with alkaline phosphatase
(Sigma Type VII-L, 400 mg/ml in 0.1 M Tris±HCl pH 8,
containing 10 mM phenylmethylsulfonyl ¯uoride) for 18 h at
37°C (Bancher et al., 1989).
The number of cells reactive for D-110 and HIF-1a was
determined in zones of active myelin destruction in 10
standardized microscopic ®elds of 10 000 mm2 each, de®ned
by an ocular morphometric grid.
Identi®cation of CDV and paramyxovirus using
RT±PCR
Total RNA was isolated from ®ve sections per case (5 mm
thick) of paraf®n-embedded formalin-®xed brain tissue as
described elsewhere (Santa et al., 1998). An aliquot of 3±5 ml
of total RNA was reverse transcribed (RT) and polymerase
chain reaction (PCR) ampli®ed using a Gene Amp RNA PCR
Core Kit (Perkin Elmer Biosystems). From each individual
RNA extraction, we performed RT±PCR to amplify a PLP-
speci®c, 124 bp PCR product using primers Oli.396 5¢ GT-
GGACATGAAGCTCTCACTG 3¢ and Oli.301 5¢GCAGTT-
CCATAGATGACATACTGGA 3¢, ¯anking PLP intron 2, as
an RNA quality control. We designed paramyxovirus (mea-
sles virus)-speci®c PCR primers Oli.422 5¢ ATGGGGGAA-
ACTGCACCTTACATGGT 3¢ and Oli.398 5¢ CCTCCCAT-
GGAGTTTTCAAGTTC 3¢ in a highly conserved region of
the nucleocapsid protein at nucleotides 1023±1152 of CDV,
complete genome (accession number gi3335048). PLP and
paramyxoviridae virus-speci®c PCRs were performed under
standard conditions at an annealing temperature of 61 and
59°C, respectively. For the detection of paramyxovirus RNA
from paraf®n-embedded human tissue, we always performed
a boosted PCR. In these cases, 1 ml of a 1 : 50 dilution of the
®rst PCR was used as a template for the second PCR. The
PLP-speci®c RT±PCR was performed as a positive control
insuring RNA quality, and a boosted PCR without template
was used as a negative control.
Western blot analysis and enzyme-linked
immunosorbent assay
Western blot analysis was performed using standard methods.
Brie¯y 13 ml of CSF (~5 mg of CSF total protein) were loaded
per well and separated in 10% BisTris (NuPage) sodium
dodecyl sulfate (SDS)±polyacrylamide gels (Novex, San
Diego, CA, USA). Separated proteins were electrotransferred
to nitrocellulose membranes (Hybond-C, Amersham
Pharmacia Biotech, Uppsala, Sweden). Ef®ciency of transfer
was monitored by the use of a pre-stained low range SDS±
polyacrylamide gel electrophoresis (PAGE) standard (Bio-
Rad, Hercules, USA) and by staining of the ®lters with
Ponceau S (Sigma, St Louis, MO, USA) after transfer. Blots
were blocked with 2% milk powder in phosphate-buffered
saline (PBS) containing 0.05% Tween-20 (PBS-T) and
probed with D-110 or HIF-1a antibodies (1 : 500 in 2%
milk powder in PBS-T) overnight at 4°C. Blots were washed
three times with PBS-T and incubated with horseradish
peroxidase-conjugated anti-mouse IgG (1 : 5000; Amersham
Pharmacia Biotech) for 1 h at room temperature. After
washing, bound antibodies were detected by enhanced
chemoluminescence (Amersham Pharmacia Biotech).
To compare D-110 antibody reactivity to phosphorylated
and dephosphorylated proteins, the blots were treated with
15 U/ml alkaline phosphatase (type III; Sigma, St Louis, MO,
USA) in 100 mM Tris±HCl pH 9.5, 50 mM MgCl2, 100 mM
NaCl overnight at 37°C. After three washes with PBS-T,
dephosphorylated proteins were incubated with D-110 anti-
body as described above.
For enzyme-linked immunosorbent assay (ELISA), CSF
proteins were covalently coupled to protein immobilizer
plates (Exiqon, Vedbaek, Denmark). To this end, 25 ml of
CSF was applied to immobilizer plates in 100 ml of 100 mM
carbonate buffer pH 9.6 for 2 h at room temperature. CSF
proteins were then incubated for 15 min with 200 ml of 2%
SDS in PBS. After six washes with PBS-T, the plates were
incubated with 100 ml of D-110 or HIF-1a antibody/well
(1 : 100 in PBS-T) overnight at 4°C, washed six times with
PBS-T and incubated with alkaline phosphatase-coupled anti-
mouse IgG (1 : 3000; Axell, Westbury, USA) for 1 h at room
temperature. After washing, the reaction products were
visualized with p-nitrophenylphosphate (Sigma) in 1 M
diethanolamine, 5 mM MgCl2 pH 9.8, and the optical density
determined at 405 nm. Control wells were incubated with
secondary antibody alone (no primary antibody) and all data
were corrected by subtraction of these background values.
Variations between single microtitre plates were determined
using CSF samples with (known) high and low D-110 values
throughout all ELISA plates used. Both the inter- and intra-
assay variations were <15%.
CDV nucleocapsid protein was expressed in the pET14
expression system (Novagen, Madison, WI, USA). The
recombinant CDV nucleocapsid protein contains an
N-terminal histidine tag in order to allow af®nity puri®cation
on an Ni-NTA±agarose column.
For production of recombinant CDV nucleocapsid protein,
Escherichia coli strain BL21(DE3) containing the N/pET14
plasmid, containing the entire CDV nucleocapsid gene, were
grown until an optical density (at 600 nm) of 0.6 was reached.
Expression of the recombinant protein was then induced by
the addition of 0.4 mM isopropyl-b-D-thiogalactopyranoside
(Roche Molecular Biochemicals, Mannheim, Germany) and
bacteria were grown for an additional 4 h. Bacteria were
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Fig. 1 Expression of D-110 antigen in multiple sclerosis and stroke lesions. (A±F) Large acute multiple sclerosis lesion in the subcortical
white matter with very intense expression of D-110 antigen. The actively demyelinating lesion was present in a 45-year-old male patient
with a clinical history of 3 weeks and followed lesional pattern III according to Lucchinetti et al. (2000). APL = acute demyelinating
plaque; WM = normal white matter. A shows the outline of the lesion in luxol fast blue myelin stain, while B documents the intense D-
110 immunoreactivity (brown) within the whole plaque area (APL). Higher magni®cation of the section shown in B reveals a high density
of brown immunoreactive cells (C), which in higher magni®cation can be identi®ed as (D) astrocytes, (E) oligodendrocytes and (F)
macrophages. Magni®cations: A and B, 35; C, 350; D, E and F, 3400. (G and H) A chronic active multiple sclerosis lesion with very
low expression of the D-110 antigen. This lesion was present in a 28-year-old male patient with 400 week disease duration and followed
pattern II (compatible with antibody-mediated demyelination) as de®ned by Lucchinetti et al. (2000). WM = periplaque white matter;
A = zone of active demyelination with granular myelin degradation products in macrophages; C = inactive plaque centre. G shows the
lesion outline in luxol fast blue myelin stain, and H the immunoreactivity for D-110, which reveals minimal staining in some cell
processes in the zone of active demyelination (A). Magni®cations: G, 3100; H, 3800. (I±L) Acute infarct in the cerebellar white matter,
stained by immunocytochemistry for D-110 antigen; there is massive expression of the antigen at the edge of the infarct (E), while the
necrotic centre (C) shows much less reactivity; there is no reactivity in the perilesional white matter (WM). At higher magni®cation, D-
110 immunoreactivity is concentrated at the edge of the infarct (K) and expressed in different cell types in the lesion (J). When the
section is pre-treated with alkaline phosphatase, immunoreactivity is completely abolished (L). Magni®cations: I, 32; J, 3200; K and L,
330.
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harvested by centrifugation and lysed in urea buffer (8 M
urea, 100 mM NaH2PO4, 10 mM Tris±HCl) pH 8.0. Crude
lysates were then cleared by centrifugation and the super-
natant was applied to an Ni-NTA±agarose column (Qiagen,
Hilden, Germany) under denaturing conditions in urea buffer.
Bound fusion proteins were eluted by a shift in pH from 8 to
4.5 and stored at ±20°C.
Anti-CDV nucleocapsid protein serum IgM and IgG
antibodies were measured by ELISA using 96-well Nunc-
Immuno Maxisorp microtitre plates (Nunc, Roskilde,
Denmark) coated with 100 ml of a 10 mg/ml recombinant
CDV nucleocapsid protein solution in PBS overnight at 4°C
(1 mg/well). A 100 ml aliquot of 10% fetal bovine serum
(FBS; Life Technologies) in PBS (FBS±PBS) was used as
background sample. Plates were then washed six times with
PBS-T and blocked with FBS±PBS for 2 h at room
temperature. After washing, 100 ml of diluted serum samples
(1 : 250 in FBS±PBS) were added and incubated for 1 h at
room temperature. Plates were washed, and 100 ml of
peroxidase-conjugated goat anti-human IgM (1 : 1000) or
IgG (1 :6000), or anti-mouse IgG secondary antibody (Dako)
in FBS±PBS were added for 1 h at room temperature with
gentle shaking. Plates were washed, and speci®c antibody
binding was visualized by the addition of 100 ml of
O-phenylendiamine (Sigma) in 0.02 M acetate buffer with
0.0004% H2O2 to each well. After 20 min, the reaction was
stopped with 50 ml of 1 M HCl, and the plates were read at
492 nm with a reference ®lter at 405 nm. All samples were
analysed in duplicate, and the optical densities of the
background wells were subtracted from the test samples. As
a control, we have used the D-110 antibody (diluted 1 : 20 000
and 1 : 40 000). Both, the inter- and intra-assay variations
were <15%.
To test for a possible cross-reactivity between human sera
and D-110 antibody, plates were coated with recombinant
CDV nucleocapsid protein and blocked with PBS±FBS as
described above. The plates were then incubated with human
sera (1 : 100 in PBS±FBS) for 1 h at room temperature,
washed and incubated with D-110 antibody (1 : 20 000 in
PBS±FBS) for 1 h at room temperature. After washing, bound
antibodies were visualized with peroxidase-conjugated goat
anti-mouse IgG secondary antibody as described above.
Cross-reactivity was measured as the percentage inhibition of
D-110 antibody binding. Alternatively, plates were incubated
with D-110 antibody (1 : 20 000 in PBS±FBS) for 1 h at room
temperature, washed, incubated with human sera (1 : 250 in
PBS±FBS) for 1 h at room temperature, and bound antibodies
were visualized with peroxidase-conjugated goat anti-human
IgM or IgG secondary antibody as described above. In this
experiment, cross-reactivity was measured as the percentage
inhibition of human serum binding
Statistical evaluation
Statistical analysis (means, standard deviations and medians),
signi®cance of group differences, linear regressions and
Pearson correlations were evaluated using the GraphPad
Prism statistical analysis program (GraphPad Software, San
Diego, CA, USA). Distribution of groups was analysed by the
Kolmogorov±Smirnov test. Between-group comparisons of
normally distributed data were then made using parametric
one-way ANOVA (analysis of variance) with the Bonferroni
post-test. P values <0.05 were considered as statistically
signi®cant.
Results
D-110 epitope is expressed in a distinct subtype
of actively demyelinating multiple sclerosis
lesions
Actively demyelinating lesions in multiple sclerosis patients
can be separated into four distinctly different patterns
(Lucchinetti et al., 2000). These patterns of demyelination
were the same in all active lesions within an autopsy of a
single patient, but differed in essential aspects of immuno-
pathology between different multiple sclerosis patients.
Fig. 2 Average number of cells with D-110 (black bars) and HIF-
1a (white bars) immunoreactivity in the lesions of different brain
diseases and normal controls. MS PIII active = actively
demyelinating multiple sclerosis lesions with pattern III
demyelination; MS others active = actively demyelinating multiple
sclerosis lesions with other patterns of demyelination (patterns I, II
and IV); MS inactive = inactive lesions from multiple sclerosis
patients; control = normal brain from control patients; stroke
active = early stroke lesions (1 week disease duration); stroke
inactive = inactive stroke lesions (>6 weeks disease duration);
HSV = herpes simplex encephalitis; PML = progressive multifocal
leucoencephalopathy; CMV = cytomegalovirus encephalitis;
FSME = European tick-borne encephalitis; HIV = human
immunode®ciency virus encephalitis; SSPE = subacute sclerosing
panencephalitis. *P < 0.01 in comparison with controls as well as
between MS PIII active and MS others active.
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Pattern I lesions are well demarcated and centred by small
vessels with focal in®ltrates of T lymphocytes and macro-
phages. Pattern II lesions are similar to those described above,
but show in addition deposition of immunoglobulins and
activated complement (C9neo antigen) at the sites of active
myelin destruction (Storch et al., 1998; Genain et al., 1999).
Pattern III lesions reveal ill-de®ned contours. The initial
lesions are characterized by a distal oligodendrogliopathy,
de®ned by extensive or complete loss of myelin-associated
glycoprotein in the zones of active myelin destruction, in
comparison with other myelin proteins, such as PLP or
myelin oligodendrocyte glycoprotein (Itoyama et al., 1980).
The subsequent demyelinating process is associated with a
high incidence of oligodendrocytes, showing the typical
morphological features of apoptosis. Pattern IV lesions are
sharply demarcated, with similar T cell and macrophage
distribution to that described for pattern I. Deposition of
immunoglobulins and activated complement is absent; there
is, however, a high incidence of oligodendrocytes with DNA
fragmentation in a narrow zone just outside the area of active
myelin destruction (Lucchinetti et al., 1996).
Massive expression of the D-110 epitope was found in all
actively demyelinating pattern III lesions (Figs 1 and 2). The
expression was most pronounced at sites of active myelin
destruction, and much lower in the inactive centre of the
plaques. Only exceptional immunoreactive cells were found
in the periplaque and distant white and grey matter.
Expression of the D-110 epitope was not restricted to a
speci®c cell type, but was found in oligodendrocytes,
astrocytes, microglia cells and macrophages (Fig. 1).
Oligodendrocytes, however, were stained most intensely
compared with other cells. In contrast to pattern III lesions,
actively demyelinating plaques following other patterns of
demyelination (patterns I, II and IV) showed only minor
immunoreactivity with this antibody regardless of the stage of
the demyelinating process, as de®ned by stringent criteria
(BruÈck et al., 1995; Figs 1 and 2). Similarly, cells with D-110
immunoreactivity were only encountered exceptionally in the
normal brain of control patients. As a positive control,
massive expression of this epitope was found in similar cell
types in dog brains infected with CDV.
D-110 expression in the multiple sclerosis brain
is not due to infection with CDV or a related
paramyxovirus
The observed expression of the D-110 epitope could re¯ect
infection of the brain of a subset of multiple sclerosis patients
with CDV or a related paramyxovirus. We therefore screened
the tissue by immunocytochemistry for other CDV antigens
or by in situ hybridization for CDV RNA sequences. As a
positive control, formalin-®xed, paraf®n-embedded brain
material from dogs with canine distemper encephalomyelitis
was used. In contrast to very strong positive signals in the
CDV-infected dog brains, we found no reactivity with any of
the other antibodies recognizing the N, H and M protein or
probes complementary to N and P of CDV in any of the
multiple sclerosis sections (data not shown).
To investigate this question further, we developed PCR
primers intended to recognize a broad variety of different
paramyxovirus strains. These PCR primers were located in a
highly conserved region of the nucleocapside protein and
were able to amplify the paramyxovirus sequence when
RT±PCR was performed from total RNA extracted from
paraf®n-embedded formalin-®xed sections of CDV-infected
dog brain or a patient with subacute sclerosing panencepha-
litis. However, in spite of positive signals for sequences of the
myelin protein PLP as an RNA quality control, we found no
ampli®ed paramyxovirus sequence in RNA isolated from
multiple sclerosis brain tissue, which presented with intensive
D-110 imunoreactivity, even when a boosted PCR was
performed (Fig. 3).
Expression of the D-110 epitope in diseases
other than multiple sclerosis
We then investigated whether the expression of the D-110
epitope is speci®c for this subset of multiple sclerosis
patients, or whether it can also be found in other brain
diseases. The most consistent expression pattern of D-110
antigen was found in ischaemic brain lesions during the
early stage of active tissue destruction (Figs 1 and 2).
There, D-110 reactivity was concentrated mainly at the
lesion border and in a small rim of perilesional white
matter, while the necrotic centre of the infarct revealed
only a few immunoreactive cells. D-110 reactivity was
present mainly in oligodendrocytes and astrocytes as well
as in some macrophages and activated microglia. In
Fig. 3 RT±PCR for the detection of nucleocapsid protein (N)- and
PLP-speci®c RNAs isolated from paraf®n-embedded formalin-
®xed brain tissue. PCR-derived fragments were separated on a 3%
agarose gel. In the upper panel, the 128 bp N-speci®c PCR
product was detected in RNA isolated from subacute sclerosing
panencephalitis and CDV, but not in cases of multiple sclerosis
material and negative control (NC). The lower panel shows the
PCR products of a PLP speci®c RT±PCR. This reaction was
performed with the same RNA as the N-speci®c RT±PCR. The
sizes of the molecular size markers (M) are indicated in base pairs
(bp) on the left.
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cortico-subcortical infarcts, D-110-reactive neurons were
also found, mainly located at the lesional edges. D-110
expression was highest during the ®rst week after onset
of stroke and declined rapidly thereafter. No expression
was noted in infarcts older than 6 weeks (Fig. 2). No D-
110 immunoreactivity was found in myocardial infarcts,
irrespective of the stage of lesion development.
In addition, we found a variable expression of this antigen
in virus-induced brain diseases (Fig. 2). An expression
comparable in cell numbers and staining intensity with that in
pattern III multiple sclerosis lesions was found in some cases
of progressive multifocal leucoencephalopathy, and in
cytomegalovirus or herpes simplex virus encephalitis.
There, the expression, as in multiple sclerosis, was restricted
to areas which were in the active stage of tissue damage.
Different cells, including oligodendrocytes, astrocytes,
microglia cells and macrophages, were stained. However,
D-110 expression was only found in a subset of cases, while
in others no staining was observed in spite of local expression
of the different disease-related virus antigens or active tissue
destruction.
The common denominator of all lesions in stroke and
encephalitis patients with high expression of the D-110
epitope was a pattern of myelin and oligodendrocyte
damage, closely re¯ecting that in multiple sclerosis
pattern III. All lesions showed a preferential loss of
myelin-associated protein and cyclic nucleotide phospho-
diesterase, as well as nuclear condensation and fragmen-
tation in oligodendrocytes.
D-110-reactive protein is liberated into the CSF
in brain disease
Analysis of the CSF of patients with multiple sclerosis and
other neurological diseases by western blot revealed at least
three immunoreactive bands of 115, 70 and 50 kDa (Fig. 4A).
We failed to detect any D-110 immunoreactivity in serum.
Next we developed an ELISA system to quantify CSF
antigens recognized by D-110. As can be seen in Fig. 5,
D-110 values were lowest in patients with `normal CSF'
(OND); only two patients with headaches showed higher
D-110 values. The ®rst attack, relapsing±remitting and
primary progressive clinical multiple sclerosis subgroups
(but not secondary chronic progressive) and stroke patients
had signi®cantly higher CSF D-110 values than the OND
controls.
From the OND group, we calculated a `cut-off' value
(mean 6 2.5 SD; 0.3 OD units). Eight out of 43 ®rst attack
patients (19%), six out of 25 relapsing±remitting patients
(24%), two out of 14 secondary chronic progressive patients
(14%), four out of 10 primary progressive patients (40%), ®ve
out of 12 stroke patients (42%), three out of 13 VND patients
(23%), two out of 10 BND patients (20%) and two out of 46
OND patients (4%) had D-110 values above this cut-off value
(>0.3).
Using recombinant CDV nucleocapsid protein as an
antigen, we screened the sera of our patients and healthy
controls for the presence of anti-CDV nucleocapsid IgM and
IgG antibodies. These antibodies were, as would be expected
owing to the sequence homology of this protein with the
nucleocapsid protein of other paramyxoviruses (such as
measles and parain¯uenza virus), present at equal titres in all
Fig. 4 (A) Reactivity of D-110 antibody with the CSF of patients
with OND (lane 1), VND (lane 2), stroke (lane 3), ®rst attack
multiple sclerosis (lane 4) and primary proliferating multiple
sclerosis (lane 5) in western blots. CSF (25 ml/lane) was separated
by SDS±PAGE, transferred to nitrocellulose membranes and
incubated with D-110. Reactive proteins were visualized with
enhanced chemiluminescence. (B) Dephosphorylation of this blot
abolished all signals. (C) The CSF of two multiple sclerosis
patients, in whom a diagnostic brain biopsy was performed: lane
6, patient with pattern III demyelinating lesion; lane 7, patient
with a pattern II demyelinating plaque. Molecular weight
standards (kDa) are shown on the left.
Fig. 5 Individual levels of D-110 immunoreactivity measured by
ELISA in the CSF of patients with multiple sclerosis, ®rst attack
(R0), relapsing±remitting (RR), secondary chronic progressive
(SP) and primary chronic progressive (PP) disease course; stroke
(Stro), viral and bacterial neurological disease (VND and BND)
and other neurological diseases (OND). Between-group
comparisons of normally distributed data were made using
parametric ANOVA with the Bonferroni post-test. Signi®cant
differences from OND are shown as *P < 0.05, **P < 0.01 and
***P < 0.001. A `cut-off' value (mean 6 2.5 SD; 0.3 OD units)
was calculated from the OND group.
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groups analysed (P > 0.05). Furthermore, we found no
correlation between serum IgM or IgG antibodies and CSF
D-110 antigen levels. We have also investigated whether
serum antibodies to CDV nucleocapsid protein are cross-
reactive with D-110 antibody by ELISA using pre-incubation
of this antigen with sera and/or D-110 antibody. However, we
found no signi®cant cross-reaction between D-110 antibody
and human sera (<10%), indicating that human serum
antibodies are not reactive with the epitope recognized by
D-110 antibody.
A retrospective analysis of the clinical course of patients
did not reveal signi®cant correlates between CSF D-110
levels and type of disease (relapsing±remitting, primary or
secondary progressive), severity of disease, conversion to
clinically de®nite multiple sclerosis, annual relapse rate or
disease progression.
Direct correlation between CSF values of D-110
with neuropathology
In four multiple sclerosis cases included in this series, both a
brain biopsy and CSF samples were available. One case,
which was classi®ed by neuropathology as pattern III
demyelination, showed signi®cantly elevated levels of the
D-110 protein in the CSF. The other three cases, showing a
pattern II lesion in pathology, only revealed CSF levels of the
D-110 epitope comparable with controls (Fig. 4C, Table 2).
Repeated CSF analysis during the disease course in the
multiple sclerosis patient with pattern III lesions showed
elevated D-110 values during the active stage of the disease,
while the levels declined below the cut-off level when the
patient entered remission, de®ned both by clinical parameters
and the disappearance of lesion enhancement in MRI.
D-110 recognizes a phosphorylation-dependent
epitope, related to brain hypoxia
Pre-treatment of brain sections with alkaline phosphatase
prior to immunocytochemistry completely abolished D-
110 immunoreactivity. To con®rm that the antibody
recognizes a phosphorylated epitope, we incubated a
western blot identical to that shown in Fig. 4A with
alkaline phosphatase. As can be seen in Fig. 4B, this
treatment abolished the binding of D-110 to CSF proteins,
thus con®rming the ®ndings from immunohistochemistry.
All brain lesions with D-110 immunoreactivity, irrespect-
ive of their primary ischaemic or in¯ammatory nature,
also showed expression of HIF-1a within nuclei of glial
cells, neurons, macrophages or endothelial cells (Fig. 2).
There was a signi®cant correlation between D-110 and
HIF-1a expression within the lesions (correlation coef®-
cient: 0.72; P < 0.0001). However, no HIF-1a-immuno-
reactive material was detected in the CSF.
Discussion
This study was designed originally to search for a possible
involvement of CDV as a trigger for multiple sclerosis.
Indirect evidence for an association between CDV infection
and multiple sclerosis comes from epidemiological studies as
well as from the increased incidence of CDV reactivity in
CSF immunoglobulins of patients (Cook et al., 1995;
Rohowsky-Kochan et al., 1995). As we had access to a
large sample of multiple sclerosis biopsies and autopsies from
the earliest stages of the disease, it was thus obvious to search
for CDV antigen and/or sequences by immunocytochemistry
and in situ hybridization. Indeed, we found a very pronounced
immunoreactivity in a particular subset of multiple sclerosis
patients with a monoclonal antibody against CDV nucleo-
capsid protein. Patients with the highest expression of this
antigen in the lesions all followed the pathological pattern III,
which in several respects, such as loss of myelin-associated
glycoprotein and oligodendrocyte apoptosis, mimics changes
previously described in virus-induced demyelinating disease
(Itoyama et al., 1982). Nevertheless, a detailed analysis of
antigens and RNA sequences from other parts of CDV
revealed no further positive results and thus rules out that the
expression of the D-110 antigen indeed re¯ects CDV
infection of the tissue. Furthermore, PCR analysis using
primers to regions conserved within the paramyxovirus
family was negative. Thus, even the possibility that D-110
recognizes a cross-reactive sequence within another member
of the paramyxovirus family seems unlikely. These results are
underscored further by the fact that this epitope can be found
in a variety of other neuropathological conditions, such as
different virus-induced brain diseases or acute stroke. All
these data strongly indicate that the D-110 antibody
recognizes a cross-reactive epitope on an endogenous protein
that is upregulated in the CNS under special pathological
conditions.
Besides in the distinct subtype of multiple sclerosis lesions,
the most pronounced expression of D-110 antigen was found
in some virus-induced lesions and in acute ischaemia. All
lesions with high D-110 expression, irrespective of the cause
of the primary disease, had in common a similar pattern of
myelin and tissue destruction, characterized by loss of
myelin-associated glycoprotein, and nuclear condensation
and fragmentation in oligodendrocytes, suggesting a common
pathogenetic pathway of tissue injury. In addition, all these
lesions showed a massive expression and nuclear trans-
location of HIF-1a. These data thus suggest that a hypoxia-
like metabolic injury may be involved in tissue damage not
only in stroke but also in in¯ammatory brain lesions.
In in¯ammatory conditions, hypoxia-like tissue damage
could result from ischaemia, induced by a disturbance of the
microcirculation due to massive focal oedema in areas which
are restricted in swelling by tight connective tissue or bony
constrains (Prineas and McDonald, 1997). Furthermore,
thrombotic occlusion of small in¯amed vessels can occur
both in virus encephalitis (Esiri and Kennedy, 1997) and in
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multiple sclerosis (Putnam, 1933; Wake®eld et al., 1994).
Alternatively, key molecules involved in tissue injury, such
as for instance excitotoxins (Oka et al., 1993; McDonald
et al., 1998) as well as reactive oxygen and nitrogen
intermediates (Smith et al., 1999), may be shared in
ischaemic as well as in¯ammatory brain lesions. In particular,
peroxynitrite may impair mitochondrial function in multiple
sclerosis lesions (Bolanos et al., 1997; Heales et al., 1999; Lu
et al., 2000) leading, as in true ischaemia, to cellular energy
de®ciency and nuclear translocation of HIF-1a (Kimura et al.,
2000; Semenza, 2000).
So far, it has not been determined which protein in the
human CNS is recognized by the D-110 antibody. This
antibody selectively detects a non-phosphorylated CDV
nucleocapsid epitope (A. Zurbriggen, unpublished) and a
phosphorylated endogenous brain-speci®c epitope. Several
examples exist where an antibody cross-reacts with a
phosphorylated epitope in one protein and a non-phosphoryl-
ated epitope in a different protein. In these cases, the
phosphorylated amino acid is substituted by a charged amino
acid such as glutamic acid or aspartic acid (Al-Hillawi et al.,
1998). Since in human brain the antibody reacts with a
phosphorylated epitope, the most likely candidate would be
an endogenous brain protein, selectively phosphorylated in a
stress response to ischaemia or a related metabolic injury.
Irrespective of the nature of this antigen, its liberation into
the CSF may have practical consequences. Although not
speci®c for multiple sclerosis, it may allow the identi®cation
of a subset of patients with a pathogenetically distinct pattern
of tissue injury. Within the population of patients with
multiple sclerosis or virus encephalitis, it may recognize
those in which hypoxia-like tissue injury contributes to the
development of the lesions. Such a paraclinical marker is the
prerequisite for the future design of subtype-speci®c thera-
peutic strategies in the respective patients. Our preliminary
data suggest that the D-110 epitope may indeed ful®l the
criteria for such a suitable paraclinical marker. In pathology,
the expression of this marker is associated with the respective
pattern of tissue injury with a very high degree of speci®city.
In the CSF of multiple sclerosis patients, this protein is
present on average in 17% of the patients, a percentage which
closely matches the incidence of cases with pattern III lesions
found in pathological investigations (Lucchinetti et al.,
2000). In addition, in the four cases where both a biopsy
and CSF sample were available, the CSF levels of D-110
immunoreactivity matched the immunopathological pattern
of the lesions. Thus, in pathology, D-110 is apparently a
reliable marker for identifying a de®ned subtype of in¯am-
matory brain lesions. Although supported by indirect evi-
dence, our data so far are too preliminary to answer the
question of whether the levels of D-110 in the CSF accurately
re¯ect the metabolic alterations within the lesions. Further
direct correlations between pathology and CSF values of D-
110 will be necessary to determine the reliability of this tool
for diagnosis and subtyping of in¯ammatory brain diseases.
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